Delivery of Platelet-Derived Growth Factor as a Chemotactic Factor for Mesenchymal Stem Cells by Bone-Mimetic Electrospun Scaffolds

The recruitment of mesenchymal stem cells (MSCs) is a vital step in the bone healing process, and hence the functionalization of osteogenic biomaterials with chemotactic factors constitutes an important effort in the tissue engineering field. Previously we determined that bone-mimetic electrospun scaffolds composed of polycaprolactone, collagen I and nanohydroxyapatite (PCL/col/HA) supported greater MSC adhesion, proliferation and activation of integrin-related signaling cascades than scaffolds composed of PCL or collagen I alone. In the current study we investigated the capacity of bone-mimetic scaffolds to serve as carriers for delivery of an MSC chemotactic factor. In initial studies, we compared MSC chemotaxis toward a variety of molecules including PDGF-AB, PDGF-BB, BMP2, and a mixture of the chemokines SDF-1α, CXCL16, MIP-1α, MIP-1β, and RANTES. Transwell migration assays indicated that, of these factors, PDGF-BB was the most effective in stimulating MSC migration. We next evaluated the capacity of PCL/col/HA scaffolds, compared with PCL scaffolds, to adsorb and release PDGF-BB. We found that significantly more PDGF- BB was adsorbed to, and subsequently released from, PCL/col/HA scaffolds, with sustained release extending over an 8-week interval. The PDGF-BB released was chemotactically active in transwell migration assays, indicating that bioactivity was not diminished by adsorption to the biomaterial. Complementing these studies, we developed a new type of migration assay in which the PDGF-BB-coated bone-mimetic substrates were placed 1.5 cm away from the cell migration front. These experiments confirmed the ability of PDGF-BB-coated PCL/col/HA scaffolds to induce significant MSC chemotaxis under more stringent conditions than standard types of migration assays. Our collective results substantiate the efficacy of PDGF-BB in stimulating MSC recruitment, and further show that the incorporation of native bone molecules, collagen I and nanoHA, into electrospun scaffolds not only enhances MSC adhesion and proliferation, but also increases the amount of PDGF-BB that can be delivered from scaffolds.

[1]  Matthew C. Phipps,et al.  Increasing the pore sizes of bone-mimetic electrospun scaffolds comprised of polycaprolactone, collagen I and hydroxyapatite to enhance cell infiltration. , 2012, Biomaterials.

[2]  Kam W Leong,et al.  Controlled release from fibers of polyelectrolyte complexes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[3]  S. Lee,et al.  Controlled release of platelet-derived growth factor from porous poly(L-lactide) membranes for guided tissue regeneration. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[4]  S. Lynch,et al.  Augment Bone Graft Products Compare Favorably With Autologous Bone Graft in an Ovine Model of Lumbar Interbody Spine Fusion , 2012, Spine.

[5]  N. Gallay,et al.  The In Vitro Migration Capacity of Human Bone Marrow Mesenchymal Stem Cells: Comparison of Chemokine and Growth Factor Chemotactic Activities , 2007, Stem cells.

[6]  R. Gay,et al.  Angiogenic and angiostatic factors in the molecular control of angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[7]  Reva M. Street,et al.  Preclinical Toxicology Studies of Recombinant Human Platelet-Derived Growth Factor-BB Either Alone or in Combination with Beta-Tricalcium Phosphate and Type I Collagen , 2010, Journal of tissue engineering.

[8]  Jay R Lieberman,et al.  The role of growth factors in the repair of bone. Biology and clinical applications. , 2002, The Journal of bone and joint surgery. American volume.

[9]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[10]  Peter X. Ma,et al.  Nanofibrous Scaffolds Incorporating PDGF-BB Microspheres Induce Chemokine Expression and Tissue Neogenesis In Vivo , 2008, PloS one.

[11]  A. Mantalaris,et al.  Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing , 2009, Expert opinion on investigational drugs.

[12]  C. Heldin,et al.  Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.

[13]  L. Snel,et al.  Safety of recombinant human platelet-derived growth factor-BB in Augment® Bone Graft , 2012, Journal of tissue engineering.

[14]  Jeffrey M Karp,et al.  Mesenchymal stem cell homing: the devil is in the details. , 2009, Cell stem cell.

[15]  A. Rot,et al.  Murine Mesenchymal Stem Cells Exhibit a Restricted Repertoire of Functional Chemokine Receptors: Comparison with Human , 2008, PloS one.

[16]  R. Coutts,et al.  Growth factors as therapeutic agents. , 1997, Instructional course lectures.

[17]  R. Ross,et al.  Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. , 1990, Biochemistry.

[18]  Devotha Nyambo,et al.  Applications: A Review , 2014 .

[19]  Robert J. Kane,et al.  Biomimetic Nanofibrous Scaffolds for Bone Tissue Engineering Applications , 2013 .

[20]  L. Ghasemi‐Mobarakeh,et al.  Electrospun composite nanofibers for tissue regeneration. , 2011, Journal of nanoscience and nanotechnology.

[21]  Y. Kato,et al.  Comprehensive analysis of chemotactic factors for bone marrow mesenchymal stem cells. , 2007, Stem cells and development.

[22]  R. Kitazawa,et al.  Expression of platelet-derived growth factor proteins and their receptor alpha and beta mRNAs during fracture healing in the normal mouse. , 1999, Histochemistry and cell biology.

[23]  V. Denaro,et al.  Electrospun scaffolds for bone tissue engineering , 2011, Musculoskeletal surgery.

[24]  J. Homsi,et al.  Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[25]  R. Ross,et al.  The B chain of PDGF alone is sufficient for mitogenesis. , 1985, The EMBO journal.

[26]  David J. Mooney,et al.  Spatio–temporal VEGF and PDGF Delivery Patterns Blood Vessel Formation and Maturation , 2007, Pharmaceutical Research.

[27]  Cameron J Wilson,et al.  Mediation of biomaterial-cell interactions by adsorbed proteins: a review. , 2005, Tissue engineering.

[28]  Hae-Won Kim,et al.  Electrospun materials as potential platforms for bone tissue engineering. , 2009, Advanced drug delivery reviews.

[29]  C. Bünger,et al.  Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells. , 1996, Bone.

[30]  Matthew C. Phipps,et al.  Mesenchymal Stem Cell Responses to Bone-Mimetic Electrospun Matrices Composed of Polycaprolactone, Collagen I and Nanoparticulate Hydroxyapatite , 2011, PloS one.

[31]  A. Mikos,et al.  Electrospinning of polymeric nanofibers for tissue engineering applications: a review. , 2006, Tissue engineering.

[32]  R. Ross,et al.  Platelet-derived growth factor in vivo: levels, activity, and rate of clearance. , 1984, Blood.

[33]  F. Frommlet,et al.  Platelets are mitogenic for periosteum‐derived cells , 2003, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[34]  S. Lynch,et al.  Recombinant human platelet-derived growth factor: biology and clinical applications. , 2008, The Journal of bone and joint surgery. American volume.

[35]  Peter X Ma,et al.  Biomimetic nanofibrous scaffolds for bone tissue engineering. , 2011, Biomaterials.

[36]  F. Javed,et al.  Significance of the platelet-derived growth factor in periodontal tissue regeneration. , 2011, Archives of oral biology.

[37]  L. Applegate,et al.  Regulation of proliferation and differentiation of human fetal bone cells. , 2011, European cells & materials.

[38]  William V Giannobile,et al.  Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[39]  C. Ladd,et al.  Determination and expression of platelet-derived growth factor-AA in bone cell cultures. , 1992, Endocrinology.

[40]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[41]  Hang Lin,et al.  The effect of collagen-targeting platelet-derived growth factor on cellularization and vascularization of collagen scaffolds. , 2006, Biomaterials.

[42]  E. Canalis,et al.  Role of platelet derived growth factor in bone cell function. , 1992, Growth regulation.

[43]  C. Heldin,et al.  Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Zhifeng Xiao,et al.  Direct chemical cross-linking of platelet-derived growth factor-BB to the demineralized bone matrix improves cellularization and vascularization. , 2009, Biomacromolecules.

[45]  D. Prockop,et al.  Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair—Current Views , 2007, Stem cells.

[46]  S. Ahmed,et al.  Biology and clinical applications , 2004 .

[47]  Zhi-Ren Liu,et al.  P68 RNA Helicase Mediates PDGF-Induced Epithelial Mesenchymal Transition by Displacing Axin from β-Catenin , 2006, Cell.